TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 398.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,739 shares of the biopharmaceutical company's stock after buying an additional 218,766 shares during the period. Voya Investment Management LLC owned approximately 0.18% of TG Therapeutics worth $8,240,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in TGTX. Quadrant Capital Group LLC boosted its holdings in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares during the period. Blue Trust Inc. lifted its position in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its position in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC purchased a new stake in TG Therapeutics in the 4th quarter worth approximately $75,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

Shares of TGTX traded down $1.93 during trading hours on Friday, reaching $43.44. 4,165,093 shares of the company traded hands, compared to its average volume of 2,983,451. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $15.16 and a 12-month high of $46.48. The business has a fifty day moving average price of $38.56 and a 200-day moving average price of $33.24. The stock has a market capitalization of $6.90 billion, a P/E ratio of -434.36 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on TGTX shares. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.